Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Colorectal Neoplasms
  • Indoles
  • Proto-Oncogene Proteins B-raf
  • Receptor, Epidermal Growth Factor
  • Sulfonamides

abstract

  • Combined RAF and EGFR inhibition is well tolerated, with less cutaneous toxicity than would be expected with either agent, and results in modest clinical activity in this highly aggressive and chemoresistant subset of CRC.

publication date

  • March 15, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5546416

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-14-2779

PubMed ID

  • 25589621

Additional Document Info

start page

  • 1313

end page

  • 20

volume

  • 21

number

  • 6